Neulasta studies

Home Treatments Lifestyle Symptoms

Neulasta® is a prescription medication often referred as a white cell booster as it stimulate the production of white cells in the bone marrow. These are released into the blood stream increasing and maintaining the white blood count and hence reducing your risk of infection. A low white cell count can also delay your chemotherapy or keep you from getting your full dose. This white cell booster therefore gives you a better chance of being able to stick to your chemotherapy schedule, which most doctors agree is a great advantage to the success of your treatment. Several well conducted international studies, listed below have proven the effectiveness of Neulasta over no medication at all or the previously commonly used white cell booster Neupogen:. 

  1. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170.
  2. Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin’s lymphoma (NHL). Ann Oncol. 1994;5:895-900.
  3. de Graaf H, Willemse PHB, Bong SB, et al. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology. 1996;53:289-294.
  4. Wujcik D. Infection. In: Groenwald SL, Goodman M, Frogge MH, Yarbro CH, eds. Cancer Symptom Management. Boston, Mass: Jones and Bartlett Publishers; 1986:289-304.
  5. The Merck Manual of Medical Information—Home Edition Online. Available at: http://www.merck.com/pubs/. Accessed February 15, 2002.
  6. Link BK, Budd GT, Scott S, et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer. 2001;92:1354-1367.
  7. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of commmunity practices. J Clin Oncol. 2003;21:4524-4531.
  8. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406-411.
  9. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
  10. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901-906.
  11. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305.
  12. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, Pa: JB Lippincott; 1988:121-141.
  13. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-977.
  14. Data on file, Amgen.
  15. Neulasta® (pegfilgrastim) prescribing information, Amgen.
  16. Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-731.
  17. Green M, Koelbl H, Baselga J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29-35.
  18. Smith TJ et al. Can the Addition of Prophylactic Filgrastim Be Considered Cost Effective in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide? J Clin Oncol. 2006;24:3187-3205
  19. National Comprehensive Cancer Network. Clin Pract Guide Oncol [serial online]. Version 1.2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed May 24, 2007.

 

 


Further information: Your doctors and specialist  nurses are in an ideal position to give information relevant to your situation. Macmillan has a help line and a prize winning video available in English UK ethnic languages explaining Radiotherapy & Chemotherapy. Cancernet.co.uk is a complete cancer information resource written by an experienced team of doctors, health professionals and patients. It will help you make informed decisions and guide you through the cancer journey including information about: Optimum treatment of specific cancers e.g.Breast | Prostate | Bowel.   Common treatmentsChemotherapy | Radiotherapy | Hormones | Biological agents | Complementary.  Lifestyle and cancer: Books based on the facts | Exercise | Diet | Smoking | Sunbathing | Alcohol. Tip to help with the symptoms of cancer and side effects of treatments. Financial issues: Traveling and cancer | Travel insuranceLinks to support groups | Books | Videos | Glossary | About us | Disclaimer | Tests for cancer | Clinical trials | What is cancer | How to avoid cancer